Nanobiotix Sa ADR (NBTX)
NASDAQ:NBTX
Want to see NBTX full AI Analyst Report?
NBTX Stock Chart & Stats
$33.79
-$0.03(-1.02%)
At close: 4:00 PM EST
$33.79
-$0.03(-1.02%)
Day’s Range― - ―
52-Week Range$4.10 - $57.14
Previous CloseN/A
Volume23.08K
Average Volume (3M)86.47K
Market Cap
$2.00B
Enterprise Value$1.76B
Total Cash (Recent Filing)$52.75M
Total Debt (Recent Filing)$95.32M
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Sep 30, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding50,619,583
10 Day Avg. Volume61,931
30 Day Avg. Volume86,465
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)-11.14
Price to Sales (P/S)31.74
P/FCF Ratio-27.70
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue59.54
Enterprise Value/Gross Profit59.54
Enterprise Value/Ebitda-146.25
Forecast
1Y Price Target
$34.33Price Target Upside1.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.22
Revenue Forecast (FY)$40.46M
Bulls Say, Bears Say
Bulls Say
Extended Cash Runway Via Equity RaiseA ~$100m follow-on financing materially strengthens the company’s capital base, reducing near-term refinancing risk and enabling multi-year funding for clinical and platform programs. This durability supports execution of late-stage trials and Nanoprimer advancement without immediate dilutive or debt-driven constraints.
Strategic J&J Collaboration Reduces Funding BurdenTransferring Phase III responsibilities to Janssen materially lowers Nanobiotix’s R&D burden and cash burn, improving capital efficiency. Long-term this preserves resources to advance other platforms while retaining milestone/royalty upside from J&J-led global development and commercialization.
Curadigm (Nanoprimer) Platform Progress And IPAdvancement of the Nanoprimer platform with new patents, GMP/CMC progress and multiple MTAs diversifies long-term value beyond a single asset. Durable IP and external partner interest position Nanobiotix to capture collaborations, licensing, or royalties as large-molecule delivery needs grow.
Bears Say
Weakened CapitalizationSustained negative equity and elevated 2025 leverage constrain financial flexibility and increase insolvency risk under stress. Over the medium term this raises the probability of further financing, potential covenant constraints or dilution, and limits the company’s capacity to self-fund expensive late-stage trials.
Persistent Negative Free Cash FlowConsistent negative operating and free cash flows signal reliance on external capital to sustain operations. This structural cash burn means strategic choices and timelines depend on successful financing or milestones, increasing execution risk and potentially forcing program prioritization or slower platform scale-up.
High Reliance On Janssen For Pivotal PathWhile J&J partnership accelerates development, Nanobiotix’s regulatory and commercialization fate is largely controlled by the partner. This reduces strategic control, leaves timing and go/no-go decisions outside management’s direct influence, and creates milestone delivery and timing uncertainty for durable revenue realization.
NBTX FAQ
What was Nanobiotix Sa ADR’s price range in the past 12 months?
Nanobiotix Sa ADR lowest stock price was $4.10 and its highest was $57.14 in the past 12 months.
What is Nanobiotix Sa ADR’s market cap?
Nanobiotix Sa ADR’s market cap is $2.00B.
When is Nanobiotix Sa ADR’s upcoming earnings report date?
Nanobiotix Sa ADR’s upcoming earnings report date is Sep 30, 2026 which is in 119 days.
How were Nanobiotix Sa ADR’s earnings last quarter?
Currently, no data Available
Is Nanobiotix Sa ADR overvalued?
According to Wall Street analysts Nanobiotix Sa ADR’s price is currently Undervalued.
Does Nanobiotix Sa ADR pay dividends?
Nanobiotix Sa ADR does not currently pay dividends.
What is Nanobiotix Sa ADR’s EPS estimate?
Nanobiotix Sa ADR’s EPS estimate is -0.29.
How many shares outstanding does Nanobiotix Sa ADR have?
Nanobiotix Sa ADR has 50,619,583 shares outstanding.
What happened to Nanobiotix Sa ADR’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nanobiotix Sa ADR?
Currently, no hedge funds are holding shares in NBTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nanobiotix Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.33 (1.61% Upside)
$34.33 (1.61% Upside)
Blogger Sentiment
Bullish
NBTX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 105.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 20.6%
Last 30 Days ▲ 20.6%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Company Description
Nanobiotix Sa ADR
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
NBTX Company Deck
NBTX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Positive overall. The company reported meaningful financial and operational improvements driven by (a) removal of large development obligations via the Janssen amendment, (b) nondilutive royalty financing that materially strengthens near-term liquidity, and (c) clinical progress across multiple programs including encouraging early CONVERGE lead-in data and continued Curadigm platform advancement (patents, MTAs, CMC/GMP start). Key risks remain: the FY2025 revenue uplift is largely a one‑time accounting effect, clinical readouts (notably CONVERGE and the Phase III head & neck study) are controlled by J&J and many pivotal data points are not expected until 2027, and the stated runway depends on receipt of remaining financing and potential milestone receipts. On balance, the positives (stronger cash runway, lower burn, decreased net loss, strategic financing, multiple clinical catalysts and platform progress) outweigh the listed risks and uncertainties.View all NBTX earnings summariesNBTX Stock 12 Month Forecast
Average Price Target
$34.33
▲(1.61% Upside)
Technical Analysis
―
Bicara Therapeutics Inc.
―
Zenas BioPharma, Inc.
―
Upstream Bio, Inc.
―
Septerna, Inc.
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
11.11% Other Institutional Investors
88.88% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---